Factors influencing the onset and persistence of dyskinesia in MPTP- treated primates

Annals of Neurology

Volumn 47, Issue 4 SUPPL. 1, 2000, Pages

  Jenner, Peter ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; 4,6,6A,7,8,12B HEXAHYDRO 7 METHYLINDOLO[4,3 AB]PHENANTHRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; BROMOCRIPTINE; CARBIDOPA; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ENTACAPONE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; PERGOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DENERVATION; DRUG INDUCED DISEASE; DYSKINESIA; INVOLUNTARY MOVEMENT; MONKEY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MPTP POISONING; PRIMATES;

EID: 0034032141     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (120)

1. Obeso JA, Linazasoro G, Gorospe A, et al. Complications associated with chronic levodopa therapy in Parkinson's disease. In: Olanow CW, Obeso JA, eds. Beyond the decade of the brain. Royal Tunbridge Wells: Wells Medical, 1997;2:11-35
2. Koller WC. Adverse effects of levodopa and other symptomatic therapies: impact on quality of life of the Parkinson's disease patient. In: In: Stern MB, ed. Beyond the decade of the brain. Royal Tunbridge Wells: Wells Medical, 1994;1:31-45
3. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicentre 5-year study. Eur Neurol 1997;37:23-27
4. Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a three-year follow-up. J Neurol Neurosurg Psychiatry 1981;44:1021-1023
5. Rinne UK. Dopamine agonists as primary treatment in Parkinson's disease. Adv Neurol 1986;45:519-523
6. Rascol O. Ropinirole: clinical profile. In: Olanow CW, Obeso JA, eds. Beyond the decade of the brain. Royal Tunbridge Wells: Wells Medical, 1997;2:163-175
7. Vitek JL, Giroux M, Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol 2000;47(suppl 1):S131-S140
8. 3H]spiperone binding. Brain Res 1986;379:294-299
9. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Characterisation of dyskinesias induced by L-DOPA in MPTP-treated squirrel monkeys. Psychopharmacology 1990;102:21-27
10. Schneider JS. Levodopa-induced dyskinesia in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196
11. Pearce RKB, Jackson M, Smith L, et al. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Mov Disord 1995;10:731-740
12. Mena I, Court J, Fuenzalida PS, et al. Modification of chronic manganese poisoning: treatment with levodopa or 5-OH tryptophan. N Engl J Med 1970;282:5-9
13. Bédard PJ, Gomez-Mancilla B, Blanchette P, et al. Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey tell us? Can J Neurol Sci 1991;19:134-137
14. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990;13:448-458
15. Chase TN, Holden EM, Brody JA. Levodopa-induced dyskinesia: comparison in parkinsonism-dementia and amyotrophic lateral sclerosis. Arch Neurol 1973;29:328-330
16. Mones RJ, Elizan TS, Seigel GJ. Analysis of L-DOPA induced dyskinesia in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971;34:668-673
17. Nutt JG. Levodopa-induced dyskinesia: review, observations and speculations. Neurology 1990;40:340-345
18. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573
19. Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989;39(Suppl 2):11-19
20. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276: 374-379
21. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;12:634-638
22. Riley DE. Lack of dyskinesias or parkinsonism after long term exposure to levodopa [abstract]. Mov Disord 1997;12(Suppl 1): P3222
23. Sassin J, Taub S, Weitzman E. Abnormal behaviour patterns produced in normal monkeys by L-DOPA [abstract]. Neurology 1971;21:403
24. Sassin JF, Taub S, Weitzman ED. Hyperkinesia and changes in behaviour produced in normal monkeys by L-DOPA. Neurology 1972;22:1122-1125
25. Sassin JF. Drug-induced dyskinesia in monkeys. Adv Neurol 1975;10:47-54
26. Mones RJ. Levodopa-induced dyskinesia in the normal rhesus monkey. Mt Sinai J Med 1972;39:197-201
27. Mones RJ. Experimental dyskinesias in normal rhesus monkey. Adv Neurol 1973;1:665-669
28. Mones RJ, Pasik P, Pasik T, Wilks S. The modification of L-DOPA-induced dyskinesia in the monkey by unilateral nigral lesions. Trans Am Neurol Assoc 1973;98:234-237
29. Paulson GW. Dyskinesias in monkeys. Adv Neurol 1973;1: 647-650
30. Pearce RKB, Heikkila M, Linden I-B, et al. L-DOPA induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Brain 1999; in press
31. Falardeau P, Bouchard S, Bédard PJ, et al. Behavioural and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988; 150:59-66
32. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Differential effects of D-1 and D-2 agonists in MPTP treated primates. Functional implications for Parkinson's disease. Neurology 1990; 40:927-933
33. Bédard PJ, Gomez-Mancilla B, Blanchette P, et al. Role of selective D-1 and D-2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. Adv Neurol 1993;60:113-118
34. Bédard PJ, Gomez-Mancilla B, Blanchet P, et al. Dopamine agonists as first line therapy of parkinsonism in MPTP monkeys. In: Olanow CW, Obeso JA, eds. Beyond the decade of the brain. Royal Tunbridge Wells: Wells Medical, 1997;2:101-113
35. Gomez-Mancilla B, Bédard PJ. Effect of D-1 and D-2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 1991;259:409-413
36. Blanchet P, Bédard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 1993;267:275-279
37. Pearce RKB, Jackson M, Britton DR, et al. Actions of the D-1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-DOPA-primed common marmosets. Psychopharmacology 1999;142:51-60
38. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994; 6:889-897
39. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioural sensitivity to a novel dopamine D-2 agonist (U-91356A) in MPTP monkeys. J Pharmacol Exp Ther 1995;272:854-859
40. Blanchet PJ, Crondin R, Bédard PJ. Dyskinesia and wearing-off following dopamine D-1 agonist treatment in drug-naïve 1-methyl-4-phenyl-1,2,3,6-tettahydropyridine-lesioned primates. Mov Disord 1996;11:91-94
41. Juncos JL, Engber TM, Raisman R, Chase TN. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989;25:473-478
42. Pearce RKB, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-DOPA in the MPTP-treated marmoset. Mov Disord 1998;13:234-241
43. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956
44. Tolosa E, Marin C. Dopamine agonists in Parkinson's disease: a clinical review. In: Olanow CW, Obeso JA, eds. Beyond the decade of the brain. Royal Tunbridge Wells: Wells Medical, 1997; 2:143-161
45. Maratos E, Smith L, Jackson MK, et al. Inducing dyskinesias in MPTP-treated common marmosets: the effects of repeated treatment with combinations of L-DOPA and ropinirole [abstract]. Neurology 1998;50:135
46. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038
47. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;35:196-198
48. Jenner P, Tulloch I. The preclinical pharmacology of ropinirole-receptor interactions, antiparkinsonian activity and potential to induce dyskinesia. In: Olanow CW, Obeso JA, eds. Beyond the decade of the brain. Royal Tunbridge Wells: Wells Medical, 1997;2:115-130
49. Fici GJ, Wu H, Von Voigtlander PF, Sethy VH. D-1 dopamine receptor activity of antiparkinsonian drugs. Life Sci 1997;60: 1597-1603
50. Piercy MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neurone firing by pramipexole, a dopamine D-3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996;312:35-44
51. Perachon S, Schwartz JC, Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D-1, D-2 and D-3 receptors. Eur J Pharmacol 1999;366:293-300
52. Maratos E, Jackson MJ, Pearce RKB, et al. Comparison of repeated treatment with L-DOPA, pergolide and apomorphine on dyskinesia induction in MPTP-treated common marmosets [abstract]. Br J Pharmacol 1998;125(special Suppl):C4
53. Boyce S, Clarke CE, Luquin R, et al. Induction of chorea and dystonia in parkinsonian primates. Mov Disord 1990;5:3-7
54. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-170
55. Dolphin A, Jenner P, Marsden CD. Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity. Pharmacol Biochem Behav 1976;5:431-439
56. Butcher LL, Engel J, Fuxe K. Behavioural, biochemical and histochemical analysis of the central effects of monoamine precursors after peripheral decarboxylase inhibitor. Brain Res 1972;41: 387-411
57. Goshima Y, Veda H, Misu Y. Nanomolar L-DOPA induces basal L-glutamate release in intact striata and its augmentation in 6-OHDA-lesioned striata of awake rats [abstract]. Jpn J Pharmacol 1996;69(Suppl 1):30P
58. Papa SM, Chase TN. Levodopa-induced dyskinesia improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578
59. Blanchet PJ, Konitosiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998;13:798-802
60. Seeman P, Bzowej NH, Guan HC, et al. Human brain D-1 and D-2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1987;1:5-15
61. Morissette M, Goulet M, Calon F, et al. Changes of D-1 and D-2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of 1,-3,4-dihydroxyphenylalanine. Mol Pharmacol 1996;50:1073-1079
62. Graham WC, Clarke CE, Boyce S, et al. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D-2 but not D-1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 1990;514:103-110
63. Joyce JN, Marshall JF, Bankiewicz KS, et al. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density. Brain Res 1985;382:360-364
64. Gnanalingham KK, Smith LA, Hunter AJ, et al. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Synapse 1993;14:184-194
65. Falardeau P, Bédard PJ, Di Paolo T. Relation between brain dopamine loss and D-2 dopamine receptor density in MPTP monkeys. Neurosci Lett 1988;86:225-229
66. Tel BC, Zeng B-Y, Pearce RKB, et al. Changes in striatal preproenkephalin A (PPE-A) and preprotachykinin (PPT) mRNA expression: the effects of L-DOPA, bromocriptine, and topinirole in MPTP treated primates [abstract]. Neurology 1998;50(Suppl 4):3013
67. Gagnon C, Bédard PJ, Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists. Eur J Pharmacol 1990;178:115-120
68. 3H]SCH 23390 to D-1 receptors in the putamen of control and parkinsonian subjects. Eur J Pharmacol 1995;113:467-468
69. Rinne JO, Rinne JK, Laakso K, et al. Dopamine D-1 receptors in the parkinsonian brain. Brain Res 1985;359:306-310
70. Pierot L, Desnos C, Blin J, et al. D-1 and D-2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci 1988;86:291-306
71. 3H]SCH 23390 labeled D-1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol 1985;114: 235-237
72. Calon F, Goulet M, Blanchet PJ, et al. Levodopa or D-2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABA receptors in the striatopallidal complex. Brain Res 1995;680:43-52
73. Guttman M, Seeman P. L-DOPA reverses the elevated density of D-2 dopamine receptors in Parkinson's disease striatum. J Neural Transm 1985;64:93-103
74. 3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur J Pharmacol 1984;99:167-175
75. Cortes R, Camps M, Gueye B, et al. Dopamine receptors in human brain: autoradiographic distribution of D-1 and D-2 sites in Parkinson syndrome of different etiology. Brain Res 1989; 483:30-38
76. Hurley MJ, Jolkkonen J, Stubbs CM, et al. Dopamine D-3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res 1996;709:259-264
77. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D-1 and D-2 site binding in L-DOPA-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997;49:717-723
78. Dumartin B, Caillé I, Gonon F, Bloch B. Internalizarion of D-1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci 1998;18:1650-1661
79. Hirsch EC. Nigrostriatal system plasticity in PD: effect of dopaminergic denervation and treatment. Ann Neurol 2000; 47(suppl 1):S115-S121
80. Wichmann T, DeLong MR. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol 1996;6: 751-758
81. Levy R, Hazrati L-N, Herrero M-T, et al. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience 1997;76:335-343
82. Parent A, Cicchetti F. The current model of basal ganglia organization under scrutiny. Mov Disord 1998;13:199-202
83. Gerfen CR, Engber TM, Mahan LC, et al. D-1 and D-2 dopamine-receptor regulated gene expression of striato-GPi/nigral and striatopallidal neurons. Science 1990;250:1429-1432
84. Gerfen CR, McGinty JF, Young SW III. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci 1991;11:1016-1031
85. Herrero M-T, Levy R, Ruberg M, et al. Consequence of nigrostriatal denervation and L-DOPA therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. Neurology 1996;47:219-224
86. 67 mRNA. Eur J Neurosci 1995;7:1199-1209
87. Mitchell IJ, Luquin R, Boyce S, et al. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Mov Disord 1990;5:49-54
88. Palombo K, Porrino LJ, Bankiewicz KS, et al. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci 1990;10:860-869
89. Vila M, Levy R, Herrero M-T, et al. Metabolic activity of the basal ganglia in parkinsonian syndromes in human and nonhuman primates: a cytochrome oxidase histochemistry study. Neuroscience 1996;71:903-912
90. Zeng B-Y, Jolkkonen J, Jenner P, Marsden CD. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat. Neuroscience 1995;66:19-28
91. Jolkkonen J, Jenner P, Marsden CD. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol Brain Res 1995;32:297-307
92. Cenci MA, Lee CS, Björklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998; 10:2694-2706
93. Morissette M, Goulet M, Soghomonian JJ, et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D-2 agonist U91356A in continuous or intermittent mode of administrarion: comparison with L-DOPA therapy. Brain Res Mol Brain Res 1997;49:55-62
94. Morissette M, Grondin R, Goulet M, et al. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D-1 or D-2 receptor agonists. J Neurochem 1999; 72:682-692
95. Porrino LJ, Viola JJ, Crane AM, Pontieri FE. Alterations in opiate receptor binding in MPTP-induced hemiparkinsonian monkeys. Neurosci Lett 1991;127:155-159
96. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42:720-726
97. Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 1996;9:149-158
98. 3H]flunitrazepam autoradiography. Brain Res 1990;531:95-104
99. Pearce RKB, Zeng B-Y, Jenner P, Marsden CD. Altered striatal preproenkephalin mRNA levels in normal macaque monkeys (Macaca fascicularis) with dyskinesias induced by chronic L-DOPA administration [abstract]. Br J Pharmacol 1995;116:78P
100. Zeng B-Y, Pearce RKB, MacKenzie GM, Jenner P. Alterations in preproenkephalin and adenosme-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur J Neurosci 1999; in press
101. Gerfen CR. Dopamine-meidtaed gene regulation in models of PD. Ann Neurol 2000;47(suppl 1):S42-S52
102. Calabresi P, Giacomini P, Bernadi G. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000;47(suppl 1):S60-S69
103. Pearce RKB, Smith LA, Jackson MJ, et al. The dopamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and L-DOPA-primed common marmosets. Ann Neurol 1999; in press
104. Smith LA, Cheetham S, Maratos F, et al. BTS 74 398 reverses motor deficits in MPTP-treated common marmosets without inducing dyskinesias [abstract]. Br J Pharmacol 1998;123:253P
105. Steiner H, Gerfen CR. Dynorphin opioid inhibition of cocaine-induced, D-1 dopamine receptor-mediated immediate-early gene expression in the striatum. J Comp Neurol 1995;353:200-212
106. Xu M, Hu X-T, Cooper DC, et al. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D-1 receptor mutant mice. Cell 1994;79:945-955
107. Gerfen CR, Keefe KA, Gauda EB. D-1 and D-2 dopamine receptor function in the striatum: coactivation of D-1 and D-2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D-1-containing neurons. J Neurosci 1995;15:8167-8176
108. Brotchie JM. Adjuncts to dopamine replacement a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876
109. Martinez-Mir MI, Probst A, Palacios JM. Adenosine A2 receptors: selective localisation in the human basal ganglia and alterations with disease. Neuroscience 1991;42:697-706
110. Dixon AK, Gubitz AK, Sirinaathsinghji DJS, et al. Tissue distribution of adenosine receptor messenger-RNAs in the rat. Br J Pharmacol 1996;118:1461-1468
111. Kurokawa M, Kirk IP, Kirkpatrik A, et al. Inhibition by KF17837 of adenosine A2a receptor-mediated modulation of striatal GABA and ACh release. Br J Pharmacol 1994;113:43-48
112. Mori A, Shindou T, Ichimura M, et al. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci 1996;16:605-611
113. Brown SJ, Gill R, Evenden J, et al. Striatal A2a receptor regulates apomorphine induced turning in rats with unilateral dopamine denervation. Psychopharmacology 1991;103:78-82
114. Kanda T, Shiozaki S, Schimada J, et al. KF17837: a novel selective adenosine A2a receptor antagonist with anticataleptic activity. Eur J Pharmacol 1994;256:263-268
115. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2a antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513
116. Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A2a antagonist, KW-6002 with L-DOPA or with selective D-1 or D-2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 1999; in press
117. Lindsay RM, Altar CA, Cedarbaum JM, et al. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Exp Neurol 1993;124:103-118
118. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in GDNF-treated parkinsonian monkeys. Nature 1996;380:252-255
119. Zhang Z, Miyoshi Y, Lapchak PA, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monekys. J Pharmacol Exp Ther 1997;282: 1396-1401
120. Iravani MN, Costa S, Jackson MJ, et al. Reduction of L-DOPA induced dyskinesias following intraventricular administration of GCNF in common marmosets [abstract]. Br J Pharmacol 1999; 126(special Suppl):P232